Letter to the Editor: "Our Response to COVID-19 as Endocrinologists and Diabetologists"

We read with interest the article by Kaiser et al highlighting some relevant aspects about the management of patients with endocrine conditions who are simultaneously infected with the 2019 novel coronavirus (SARS-CoV-2) (1). As far as we are concerned, understanding the evidence of the role played by corticosteroids in SARS-CoV-2 infection is of immediate clinical importance. The existing literature does not currently provide conclusive evidence regarding their administration for the treatment of COVID-19 (2). There have been a number of reports stating generally positive outcomes upon corticosteroid use, especially in the early acute phase of infection, as they are capable of reducing immune-mediated damage (3). In this regard, Fu Y et al suggest to adopt steroids in combination with the use of intravenous immunoglobulin to block Fc receptors (FcR) activation in order to prevent severe lung injury. However, such treatment remains to be clinically tested for effectiveness (4). On the other hand, patients taking supraphysiologic doses of glucocorticoids may have increased susceptibility to COVID-19 because of the immunosuppressive effects of steroids, which can be ultimately responsible for severe lymphocytopenia, thus promoting a viral rebound. Moreover, steroids have also been associated with higher risk of acute respiratory distress syndrome (ARDS) (5) and may therefore determine exaggerated pro-inflammatory responses and even worsen the clinical condition of the patients. However, in the event of COVID-19, patients on long-term steroids, or suffering from adrenal insufficiency and uncontrolled Cushing syndrome may be unable to develop a normal stress response, thus requiring a rescue dose of glucocorticoids (1). In our opinion, this evidence by Kaiser and colleagues should be extended to those patients with chronic pain on therapy with opioids. Long-term use of opioids has been associated with suppression of the hypothalamic-pituitary-adrenal (HPA) axis through the inhibition of corticotrophin-releasing hormone (CRH) and antidiuretic hormone (ADH) secretion, resulting in decreased adrenocorticotropic hormone (ACTH) release (6) and central hypocortisolism (defined as stimulated cortisol concentration of <18 μg/dL [500 nmol/L] in an insulin tolerance test) (7, 8). Further investigations on the balanced use of corticosteroids therapy in COVID-19 patients with alteration of the HPA axis due to long-term opioids or steroid treatment are necessary, since these patients represent a frail population at major risk.